CD20-positive multiple myeloma: can conventional chemotherapy still be used to achieve ideal outcome for these patients?

被引：5

作者：

Huang, Beihui ^{[1
]}

Li, Juan ^{[1
]}

Liu, Junru ^{[1
]}

Gu, Jingli ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou 510275, Guangdong, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2016年 / 57卷 / 02期

关键词：

CD20; multiple myeloma; therapy;

D O I：

10.3109/10428194.2015.1055479

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In order to ascertain clinical characteristics and outcomes of CD20 + multiple myeloma (MM) patients, we retrospectively analyzed 331 newly diagnosed patients with multiple myeloma in our center. The clinical characteristics, cell morphology, immunophenotype, and cytogenetic were different between the CD20 + and CD20 - group. The median course of treatment to >= nCR (near complete recovery) were 4.5 in the CD20+ group and 2 in the CD20 - group. Excluding the IgD type, overall survival (OS) and progression-free survival (PFS) in the CD20 + group were higher than that in the CD20 - group. There were no statistically significant differences in PFS and OS in CD20+ patients after treatment with conventional regimens, novel drugs +/- transplant, nor statistical significance between those with the response >= nCR and > nCR after treatment. In conclusion, CD20-positive myeloma cells are a cluster with heterogenous clinical characteristics, cell morphology, immunophenotype and cytogenetics. For these non-IgD CD20 + MM patients, conventional therapy might be a choice to achieve an ideal outcome.

引用

页码：335 / 340

页数：6

共 14 条

[1]

Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x

[2] Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology [J].

Goasguen, JE ;

Zandecki, M ;

Mathiot, C ;

Scheiff, JM ;

Bizet, M ;

Ly-Sunnaram, B ;

Grosbois, B ;

Monconduit, M ;

Michaux, JL ;

Facon, T .

LEUKEMIA RESEARCH, 1999, 23 (12) :1133-1140

[3] Is CD20 positive plasma cell myeloma a unique clinicopathological entity? A study of 40 cases and review of the literature [J].

Grigoriadis, George ;

Gilbertson, Michael ;

Came, Neil ;

Westerman, David ;

Fellepa, Frank ;

Jene, Nick ;

Chapple, Peter ;

Juneja, Surender .

PATHOLOGY, 2012, 44 (06) :552-556

[4] Clinical, Immunophenotypic, and Genetic Characterization of Small Lymphocyte-Like Plasma Cell Myeloma A Potential Mimic of Mature B-Cell Lymphoma [J].

Heerema-McKenney, Amy ;

Waldron, James ;

Hughes, Steven ;

Zhan, Fenghuang ;

Sawyer, Jeffery ;

Barlogie, Bart ;

Shaughnessy, John D., Jr. .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 133 (02) :265-270

[5]

Kyle RA, 2003, BRIT J HAEMATOL, V121, P749

[6]

Li Juan, 2008, Zhonghua Yi Xue Za Zhi, V88, P2140

[7] Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma [J].

Lin, P ;

Owens, R ;

Tricot, G ;

Wilson, CS .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 121 (04) :482-488

[8] CD20-positive multiple myeloma - differential expression of cyclins D1 and D2 suggests a heterogeneous disease [J].

Quinn, John ;

Percy, Laura ;

Glassford, Janet ;

Somana, Kathy ;

Rodriguez-Justo, Manuel ;

Yong, Kwee .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (01) :156-159

[9] CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma [J].

Robillard, N ;

Avet-Loiseau, H ;

Garand, R ;

Moreau, P ;

Pineau, D ;

Rapp, MJ ;

Harousseau, JL ;

Bataille, R .

BLOOD, 2003, 102 (03) :1070-1071

[10] CELL-SURFACE MARKERS IN MULTIPLE-MYELOMA [J].

RUIZARGUELLES, GJ ;

SANMIGUEL, JF .

MAYO CLINIC PROCEEDINGS, 1994, 69 (07) :684-690

← 1 2 →